NCT03764631 - Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration | Biotech Hunter

Enrollment

1,502

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

January 11, 2021

Study Completion Date

January 11, 2021

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Empagliflozin

Drug

DRUG

Dipeptidyl-peptidase 4 (DPP-4) inhibitors

Dipeptidyl-peptidase 4 - Drug

Trial Locations (21)

11525

Obesity, Endocrine and Metabolism Center, Riyadh

11533

Riyadh Medical Center, Riyadh

13214

Alalam Medical Center, Riyadh

21214

DAFA Special Polyclinic, Jeddah

21412

Ghassan Najeeb Pharaon Hospital, Jeddah

21451

International Medical Center, Jeddah

21452

Dr.Bakhsh Hospital, Jeddah

21461

Dr. Soliman Fakeeh Hospital, Jeddah

Saudi German Hospital, Jeddah

21573

Al Abeer Medical Center, Jeddah

Al-Abeer Medical Center, Jeddah

21944

Al Hada Armed Forces Hospital, Ta'if

23531

Al Abeer Polyclinic, Jeddah

24232

Al Rahman Polyclinic, Mecca

Shifa Hospital, Mecca

24241

Al-Noor Specialist Hospital, Mecca

46455

Al Amal Medical Group, Yanbu

Alansari Specialist Hospital, Yanbu

47311

Prince Fahad bin Sultan hospital, Tabuk

61431

Abha International Private Hospital, Abhā

66261

Al Zafer Hospital, Najrān